Saudi Arabia Genomics Market Overview, 2030

Saudi Arabia is actively using genomics across healthcare, agriculture, and sustainability sectors, with major focus on clinical diagnostics and public health. Genomic applications in diagnostics have grown significantly, especially for identifying hereditary conditions, cancer mutations, and rare diseases. Oncology leads this space, as tumor gene sequencing allows oncologists to select targeted therapies for individual patients. In cardiology, genetic tests are being used to detect inherited heart disorders, which are highly relevant due to the high prevalence of consanguineous marriages. Rare disease diagnosis has also improved through next-generation sequencing, helping uncover gene-linked conditions common in certain Saudi families. Infectious disease control is another important area, where genomics supports pathogen tracing, antimicrobial resistance profiling, and outbreak management, including the country’s surveillance response during the COVID-19 pandemic. Pharmacogenomics is becoming mainstream in hospitals and academic medical centers in Riyadh and Jeddah, helping clinicians tailor drug therapies based on individual genetic profiles. This approach enhances treatment efficacy and reduces adverse reactions, especially for chronic diseases like hypertension and diabetes. The Saudi Human Genome Program (SHGP), launched in 2013, is central to the country’s genomics strategy. This national project aims to map the genetic makeup of Saudi citizens, helping researchers identify disease-causing mutations specific to the local population. Insights from this program feed into precision medicine, reproductive health, and population genomics. Beyond human health, genomics is also transforming agriculture and livestock in Saudi Arabia. Genomic selection is applied in livestock breeding to improve disease resistance, fertility, and productivity of native breeds. In crops, genome-based research supports the development of drought-resistant varieties suited for the desert environment, aligning with Saudi food security initiatives. Reproductive genomic tools are commonly used in preimplantation genetic diagnosis (PGD), carrier screening, and prenatal tests to detect inherited conditions. Nutrigenomics is a growing field in Saudi Arabia’s wellness industry, where genetic data is used to personalize diet plans, especially in urban wellness centers and private clinics.

According to the research report, ""Saudi Arabia Genomic Market Overview, 2030,"" published by Bonafide Research, the Saudi Arabia Genomic market is anticipated to grow at more than 15.73% CAGR from 2025 to 2030. This expansion is supported by rising public expenditure and a deliberate alignment with Saudi Arabia's national development strategy, Vision 2030. With genomics at the heart of early disease identification and individualized medicine approaches, the Vision places a strong emphasis on improving preventative healthcare. Fueled by domestic programs and partnerships with worldwide genomics research organizations, the market is currently modest in size when compared to market leaders but is growing quickly. The emphasis on preventative genomic medicine is one of the main factors driving this expansion. Saudi Arabia has made genomics a priority in order to lessen the burden of hereditary diseases because consanguinity has resulted in a somewhat high rate of inherited genetic illnesses. The Saudi Genome Program (SGP), which has made it easier to gather and analyze genomic data across the board, especially among families with a history of genetic illnesses, demonstrates this emphasis. The advent of thorough family-based genomic screening programs, with the goal of making pre-marital and prenatal genomic testing the norm in healthcare, is a noteworthy advancement. With cutting-edge facilities for genomic diagnostics and research, the King Faisal Specialist Hospital and Research Center (KFSHRC) is a crucial hub for genomics. Furthermore, the ecosystem is expanding thanks to the contributions of organizations like the King Abdullah International Medical Research Center (KAIMRC) and new biotechnology businesses. The incorporation of genomics into sports performance optimization is a developing trend. Genetic testing for athletic potential, injury risk, and dietary needs is gaining traction in the sports industry and among fitness experts, providing individualized approaches for improving physical performance. Technological progress, government backing for policies, and private sector participation which will help revolutionize both healthcare outcomes and scientific innovation.

Sequencing kits, reagents, consumables, DNA/RNA extraction kits, microarray chips, PCR kits, and bioinformatics tools are the main components of genomic products. These products are widely used in gene expression studies, genetic screening, diagnostics, and genomic sequencing. Through partnerships or distributors, major international companies like Thermo Fisher Scientific, Illumina, and Qiagen have a strong presence in the Saudi market, which has seen a considerable increase in demand for high-throughput Next-Generation Sequencing (NGS) products due to the Saudi Genome Program (SGP) itself. The national programs that are driving the use of NGS, PCR, and microarrays as technologies to diagnose heritable illnesses and improve precision medicine are the forces behind the demand for these products. These products have healthcare applications, especially in fields like metabolic diseases, rare genetic diseases, and oncology, for individualized diagnosis, disease prevention, and therapeutic decision-making. Saudi universities and research institutions that conduct genetic studies on particular populations are supported by genomic goods in their research. Research organizations such the King Abdulaziz City for Science and Technology (KACST), the King Faisal Specialist Hospital & Research Centre (KFSH&RC), and academic institutions working together on national genomic projects are among the major users of genomic products in Saudi Arabia. These items are used for public health testing through programs supported by the government. The services offered include genetic counseling, pharmacogenomics analysis, genotyping, exome sequencing, and whole genome sequencing. Key services are offered by local centers like the Saudi Human Genome Center and G42 Healthcare, which is based in the UAE but operates in the GCC. In Saudi Arabia, genomic services are used in a variety of industries, from clinical diagnostics and oncology to population health management and rare disease screening. These services are catered to both academic research and clinical diagnostics.

The Saudi Arabian genomics market is heavily influenced by developments in a wide range of genomic technologies, each of which has a critical role in influencing the nation's healthcare and research environment. Next-generation sequencing (NGS) continues to be at the forefront, making a major contribution to the success of the Saudi Genome Program (SGP). Essential for discovering disease-causing mutations common in Saudi Arabia's gene pool, particularly those related to metabolic and hereditary diseases, is the high-throughput, quick, and affordable sequencing of huge populations made possible by NGS. The most popular NGS platforms used in national research organizations are provided by major suppliers such as Illumina and Thermo Fisher Scientific. In Saudi Arabia, the polymerase chain reaction (PCR) remains a cornerstone technology for genomics, notably for genetic screening, pathogen identification, and molecular diagnostics. PCR is a crucial component of daily medical practice and was used widely throughout the COVID-19 epidemic, solidifying its place in clinical genomics. Quantitative PCR (qPCR) and digital PCR are now used more frequently to identify specific genetic mutations. Although older, Sanger Sequencing remains widely used in clinical settings for small-scale targeted sequencing or for verifying the findings of NGS, especially for pharmacogenomics research and hereditary disease screening. Microarrays are essential for gene expression profiling and single nucleotide polymorphism (SNP) identification, particularly in the context of hereditary disease screening and pharmacogenomics studies. In Saudi genomics, especially in cellular-level genetic investigations and oncology research, flow cytometry, which was formerly employed in immunology, has become more popular. New technologies are gradually being adopted for sophisticated genomic research and precision medicine applications, such as CRISPR-based diagnostics and single-cell sequencing. Saudi Arabia's embrace of a variety of genomic technologies demonstrates a dual focus: improving population-level genomic research through NGS and fostering customized healthcare delivery through PCR, microarrays, and related technologies.

The genomics industry is growing steadily in Saudi Arabia, with applications in a variety of industries including healthcare, research, and agriculture. The basis of genomic applications, especially in the identification and treatment of inherited illnesses, malignancies, cardiovascular diseases, infectious diseases, and uncommon disorders, is diagnostics. The goal of the Saudi Genome Program (SGP) is to lessen the impact of genetic disorders, which are somewhat common as a result of consanguineous marriages, and it has placed a high priority on diagnostic genomics. Genomic diagnostics with a focus on oncology are becoming more prevalent, enabling earlier diagnosis and customized cancer therapy. The COVID-19 epidemic gave infectious disease genomics more prominence, which improved pathogen monitoring and response. The integration of genomics is becoming more and more prevalent in the crucial area of drug discovery and development. Pharmaceutical businesses and research organizations in Saudi Arabia are utilizing genomic data to identify new medication targets, enhance effectiveness, and reduce negative drug responses, all of which are contributing to the growth of pharmacogenomics in the nation. In Saudi Arabia, precision medicine is becoming a revolutionary strategy for providing healthcare. Clinicians can now customize treatments to each patient's genetic profile, particularly in oncology and metabolic illnesses, thanks to genomic insights. The incorporation of genomics into standard clinical practice has been hastened by the government's dedication to creating customized healthcare frameworks. Saudi Arabia utilizes genomic approaches in the fields of agriculture and animal genomics to increase crop resilience and livestock production, thereby addressing the food security issues brought about by its arid environment. Research institutions work with agriculture ministries to create stress-tolerant plant types and improve animal breeding programs. Noteworthy uses include gene therapy research, which is still in its infancy, and prenatal and neonatal screening, which allows for the early detection of genetic disorders. Furthermore, genomics is starting to have an impact on Saudi Arabia in areas like forensic science and ancestry testing.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Genomic Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product & Services
• Products
• Services

By Technology
• Next-Generation Sequencing (NGS)
• PCR
• Microarrays
• Sanger Sequencing
• Flow Cytometry
• Others

By Application
• Diagnostics (Oncology, Cardiology, Rare Diseases, Infectious Diseases, Others)
• Drug Discovery and Development
• Precision Medicine
• Agriculture & Animal Genomics
• Other Applications Show more